Changes in plasma Apelin and Visfatin levels and relevant factors in the population with different glucose tolerance

Abstract:

Objective：To investigate the changes in plasma Apelin and Visfatin levels in the population with different glucose toler－ance and to explore their correlation with body mass index（BMI），waist hip ratio（WHR），blood glucose，plasma insulin levels as well as other factors. Methods：Plasma levels of Apelin and Visfatin levels in the fasting plasma were assayed by ELISA in patients with type 2 diabetes mellitus（T2DM），impaired glucose tolerance（IGT），and controls. Relationship between plasma Apelin，Visfatin levels and BMI，HOMA-insulin resistance index，blood lipid，fasting plasma glucose（FPG），plasma insulin levels were also analyzed. Re－sults：（1）There was no difference in plasma Apelin levels among groups（F=0.145，P >0.05）. Levels of plasma Visfatin in T2DM pa－tients were significantly reduced compared with those in controls and IGT patients（11.88±8.33（μg/L） vs. 18.10±5.83（μg/L），P=0.000；11.88±8.33（μg/L） vs. 17.83±11.88（μg/L），P=0.000） and levels of plasma Visfatin in IGT patients were significantly re－duced compared with those of controls（17.83±11.88（μg/L） vs. 18.10±5.83（μg/L），P=0.024）. （2）Plasma Apelin levels were posi－tively correlated with total cholesterol（TC），low density lipoprotein-cholesterol and FPG（r=0.30，P=0.021；r=0.32，P=0.015；r=0.29，P=0.027） and were negatively with systolic blood pressure（SBP）and diastolic blood pressure（DBP）（r=-0.36，P=0.006；r=-0.30，P=0.020）. Visfatin levels were positively correlated with WHR（r=0.51，P=0.000） and were negatively with glycosylated hemoglobin A1c（HbA1c）（r=-0.29，P=0.025）. （3）Multiple regression analysis showed that SBP，FPG，Visfatin，TC and free fatty acids were indepen－dent related factors influencing plasma Apelin levels，and WHR，HbA1c，Apelin and DBP were independent related factors influenc－ing plasma Visfatin levels. Conclusions：Changes of Apelin and Visfatin levels are associated with glucose metabolism，and they may contribute，in part，to the pathogenesis of diabetes and obesity.